Top Page
Everest Medicines Ltd.
(1952)
Everest Medicines Ltd. (1952) vs. iShares MSCI Hong Kong ETF (EWH)
Everest Medicines Ltd. Business Overview & Revenue Model
Everest Medicines Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 851.28M | 706.68M | 125.93M | 12.79M | 54.00K | 0.00 |
| Gross Profit | 597.21M | 528.89M | 91.52M | 8.15M | 31.00K | 0.00 |
| EBITDA | -276.68M | -670.04M | -744.63M | -198.91M | -972.78M | -683.03M |
| Net Income | -658.75M | -1.04B | -844.46M | -247.28M | -1.01B | -5.68B |
Balance Sheet | ||||||
| Total Assets | 4.93B | 4.96B | 5.77B | 6.61B | 6.65B | 7.48B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 1.60B | 2.35B | 1.65B | 2.64B | 4.48B |
| Total Debt | 708.72M | 575.61M | 510.63M | 534.64M | 485.03M | 447.33M |
| Total Liabilities | 1.01B | 886.05M | 804.10M | 960.25M | 753.83M | 636.11M |
| Stockholders Equity | 3.93B | 4.07B | 4.97B | 5.65B | 5.89B | 6.84B |
Cash Flow | ||||||
| Free Cash Flow | -205.84M | -744.92M | -1.04B | -1.59B | -1.71B | -991.83M |
| Operating Cash Flow | -181.47M | -679.51M | -769.19M | -1.16B | -729.94M | -471.90M |
| Investing Cash Flow | 423.71M | 974.40M | 752.50M | -1.03B | -975.82M | -519.93M |
| Financing Cash Flow | 171.64M | 37.80M | 10.10M | -25.31M | -76.51M | 5.64B |
Everest Medicines Ltd. Technical Analysis
Everest Medicines Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$11.72B | 15.25 | 6.69% | 3.96% | -8.54% | -9.46% | |
53 Neutral | HK$9.65B | -16.79 | -42.46% | ― | 1219.19% | 25.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$15.99B | -20.63 | -15.75% | ― | 102.73% | 38.42% | |
41 Neutral | HK$16.14B | ― | -8.79% | ― | 964.40% | 65.90% | |
40 Underperform | HK$21.45B | -111.85 | -3.06% | ― | 68.75% | 55.64% | |
39 Underperform | HK$10.82B | -51.69 | -21.42% | ― | 240.05% | -140.09% |
Everest Medicines Ltd. Corporate Events
Everest Medicines Ltd. announced the grant of 1,237,374 options to Mr. Yifang Wu, an executive director and chairman of the board, under the Post-IPO Share Option Scheme. This move is part of the company’s strategy to align its remuneration policy with market standards and enhance operational efficiency. The options, which have no performance targets, are set to vest equally over four years and are expected to contribute to the company’s sustainable development and good corporate governance.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. announced significant changes in its board of directors, effective October 10, 2025. Mr. Wei Fu has been re-designated as a non-executive director and appointed as honorary chairman, stepping down from his roles as chairman of the board and committees to focus on other business endeavors. Mr. Yifang Wu has been appointed as the new executive director and chairman, indicating a strategic leadership transition aimed at guiding the company’s future growth and operations.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. has announced the composition of its board of directors, which includes a mix of executive, non-executive, and independent non-executive directors. This announcement reflects the company’s commitment to strong governance and strategic oversight, which is crucial for its continued growth and competitive positioning in the biopharmaceutical industry.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. announced the grant of 74,000 options under its Post-IPO Share Option Scheme and 234,800 awards under its Pre-IPO ESOP on October 2, 2025. These grants are part of the company’s strategy to attract, retain, and incentivize employees, aligning with its remuneration policy to enhance operational efficiency. The options have a seven-year exercise period with a vesting schedule over four years, and they do not include performance targets, which the Remuneration Committee considers competitive and consistent with the company’s objectives.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Limited has announced its unaudited interim results for the first half of 2025, which have been reviewed by its audit committee and auditors, Ernst & Young. The results, available in both Chinese and English, are accessible on the company’s and the Stock Exchange’s websites, with printed versions to be distributed to shareholders by the end of September 2025. This announcement underscores the company’s commitment to transparency and compliance with the Hong Kong Stock Exchange’s listing rules, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$61.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. has announced a board meeting scheduled for August 28, 2025, to consider and approve the interim results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Limited has announced a strategic investment by subscribing to 15,846,154 American depositary shares of I-Mab, a U.S.-based biotech company specializing in precision immuno-oncology agents. This investment, valued at approximately US$30.9 million, allows Everest to hold a 16.1% stake in I-Mab, enhancing its presence in the U.S. market and complementing its existing investments in mRNA cancer vaccines. The acquisition is expected to leverage I-Mab’s clinical capabilities in the U.S. and synergize with Everest’s strong presence in Asia, potentially strengthening its industry positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. announced the completion of a placing and subscription agreement, resulting in the successful placement of 22,561,000 shares and raising approximately HK$1,553.39 million. The proceeds will be used for research and development, commercialization efforts, and general business operations, with a focus on advancing pipeline products and launching new medicines.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. has announced a strategic financial maneuver involving the placement of existing shares and a top-up subscription of new shares under a general mandate. The transaction is expected to raise approximately HK$1,553.39 million in net proceeds, which the company plans to utilize for strategic purposes. This move could potentially strengthen Everest Medicines’ financial position and support its ongoing efforts to expand its market presence in the biopharmaceutical industry. However, the completion of these transactions is contingent upon certain conditions being met, and stakeholders are advised to exercise caution.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.